BIONIME (4737) reported revenue of NT$154.1 million for Oct 2026, +12.2% year on year and -14.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.46 billion (-5.6% year on year).
In Oct 2026, it ranked No. 53 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$154.1 million | +12.2% | -14.4% |
| Sep 2026 | NT$180 million | +20.9% | +20.0% |
| Aug 2026 | NT$150 million | -10.3% | +2.9% |
| Jul 2026 | NT$145.7 million | +2.4% | +1.5% |
| Jun 2026 | NT$143.6 million | -6.5% | +1.3% |
| May 2026 | NT$141.7 million | -13.5% | +0.3% |
| Apr 2026 | NT$141.3 million | -8.4% | -15.6% |
| Mar 2026 | NT$167.5 million | +4.7% | +51.5% |
| Feb 2026 | NT$110.6 million | -28.9% | -13.1% |
| Jan 2026 | NT$127.2 million | -23.3% | -20.9% |
| Dec 2025 | NT$160.9 million | +12.8% | +25.0% |
| Nov 2025 | NT$128.7 million | -29.1% | -6.3% |
| Oct 2025 | NT$137.3 million | -22.8% | -7.8% |
| Sep 2025 | NT$148.9 million | -8.1% | -10.9% |
| Aug 2025 | NT$167.2 million | +0.2% | +17.5% |
| Jul 2025 | NT$142.3 million | -10.6% | -7.4% |
| Jun 2025 | NT$153.6 million | -9.8% | -6.2% |
| May 2025 | NT$163.7 million | -2.1% | +6.1% |
| Apr 2025 | NT$154.3 million | +12.4% | -3.5% |
| Mar 2025 | NT$159.9 million | -9.7% | +2.8% |
| Feb 2025 | NT$155.6 million | +10.9% | -6.2% |
| Jan 2025 | NT$165.9 million | +9.8% | +16.3% |
| Dec 2024 | NT$142.6 million | -21.0% | -21.5% |
| Nov 2024 | NT$181.6 million | +37.0% | +2.0% |
| Oct 2024 | NT$178 million | +0.9% | +9.8% |
Jan–Oct 2026 cumulative: NT$1.46 billion (-5.6% YoY)
Other Biotech & Medical companies
Compare with peers: BIONIME vs PEC / BIONIME vs Lotus Pharm / BIONIME vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16